Nice Earnings report = WANG & LEE GROUP, INC. Announces Fiscal Year 2023 Financial Results
HONG KONG, China, April 18, 2024 (GLOBE NEWSWIRE) -- WANG & LEE GROUP, Inc. (Nasdaq: WLGS) (“WLGS” or the “Company”), is a British Virgin Islands holding company with operations conducted by its subsidiaries in Hong Kong. The Company is a construction prime and subcontractor engaging in the installation of Electrical & Mechanical Systems (“E&M”), which include low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning (“MVAC”) systems, fire service systems, water supply and sewage disposal system installation and fitting out for the public and private sectors. The Company today announced its unaudited operating results for the year ended December 31, 2023.

Financial Highlights for the Fiscal Year 2023:

? Revenue increased by 63.7% to $6.83 million for the fiscal year 2023 ended December 31, 2023, from $4.17 million for the fiscal year ended December 31, 2022

? Gross profit increased by 210.6% to $2.44 million for the fiscal year 2023 ended December 31, 2023, from $0.79 million for the fiscal year ended December 31, 2022, respectively.

? Total shareholders’ equity increased by 449.0% to $5.98 million for the fiscal year ended December 31, 2023, from deficit of $1.71 million for the year ended December 31, 2022

Mr. Pui Lung Ho, Chief Executive Officer of the Company, commented: “During the fiscal year 2023, we continue to enhance the diversity of our product and service line by introducing new products and services, expanding into target markets, and offering products with different features and offering products with different features and functionalities to meet a broader range of customer needs, which is demonstrated by the Company’s sales growth of over 63% in the fiscal year 2023.”

Below is the summary presenting the Company’s revenues disaggregated by products and services:

Fiscal Year 2023 Financial Results Overview

Other Key Performance Indicators

Adjusted EBITDA and Adjusted EBITDA Margin

Adjusted EBITDA represents net income before interest expense, net, provision (benefit) for income taxes, and depreciation. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of revenues for each period. These metrics are supplemental measures of our operating performance that are neither required by, nor presented in accordance with, GAAP. These measures should not be considered as an alternative to net income, or any other performance measure derived in accordance with GAAP as an indicator of our operating performance. We present Adjusted EBITDA and Adjusted EBITDA Margin as management uses these measures as key performance indicators, and we believe they are measures frequently used by securities analysts, investors and other parties to evaluate companies in our industry. These measures have limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of our results as reported under GAAP.

Our calculation of Adjusted EBITDA and Adjusted EBITDA Margin may not be comparable to similarly named measures reported by other companies. Potential differences between our measure of Adjusted EBITDA compared to other similar companies’ measures of Adjusted EBITDA may include differences in capital structures, tax positions and the age and book depreciation of tangible assets.

The following table presents a reconciliation of net income, the most directly comparable measure calculated in accordance with GAAP, to Adjusted EBITDA, and the calculation of Adjusted EBITDA Margin for each of the periods presented.

Reconciliation To GAAP Information:

2023 2H 2023 1H For the years ended December 31,
(Q3 & Q4) (Q1 & Q2) 2023 2022

Consolidated Net Income (Loss) (GAAP) $ 1,295,994 $ (1,624,099 ) $ (328,105 ) $ (596,881 )
Interest expenses 36,967 24,597 61,564 35,377
Income taxes - - - -
Depreciation 31,799 614 32,413 2,603

Adjusted EBITDA (Non-GAAP) $ 1,364,760 $ (1,598,888 ) $ (234,128 ) $ (558,901 )

Adjusted EBITDA Margin 25.32 % (111.29 )% (3.43 )% (13.40 )%

Results of Operations

For the second half and the first half for the fiscal Year 2023, the years ended December 31, 2023 and 2022,

The following table sets forth a summary of our consolidated results of operations for the second half and the first half for the fiscal Year 2023, the years ended December 31, 2023 and 2022. The historical results presented below are not necessarily indicative of the results that may be expected for any future period.

For the years ended
December 31,
2023 2H
(Q3 & Q4) 2023 1H
(Q1 & Q2) 2023 2022

Contract revenue $ 5,389,143 $ 1,436,736 $ 6,825,879 $ 4,169,931
Contract costs (3,201,025 ) (1,184,254 ) (4,385,279 ) (3,384,227 )
GROSS PROFIT $ 2,188,118 $ 252,482 $ 2,440,600 $ 785,704

Less: General and administrative expenses (997,080 ) (1,893,861 ) (2,890,941 ) (1,427,156 )
Add: Other income 104,956 17,280 122,236 44,571
Less: Provision for Income Taxes - - - -
NET PROFIT / (LOSS) $ 1,295,994 $ (1,624,099 ) $ (328,105 ) $ (596,881 )

Foreign Currency Translation Adjustment 24,971 (3,459 ) 21,512 (130 )
TOTAL COMPREHENSIVE INCOME / (LOSS) $ 1,320,965 $ (1,627,558 ) $ (306,593 ) $ (597,011 )

Revenue

Our sales were $5.39 million for the second half of the fiscal year 2023, which increased by $3.95 million, or 275.1% from $1.44 million for the first half of the fiscal year 2023.

Our sales were $6.83 million for the fiscal year 2023 ended December 31, 2023, which increased by $2.66 million, or 63.7% from $4.17 million for the same period of 2022. During the fiscal year 2023, one of our largest construction projects was suspended since the first quarter of 2023 until July 2023 due to work delays caused by a third party to our client. Since the revenue is recognized based on the stages of site work, we posted a relatively low revenue in the first half year of the fiscal year 2023 comparing to the second half year of the fiscal year 2023. We successfully charged the client for the loss and damage caused by the suspension while resume the site work.

Cost of revenues

Our cost of revenues were $3.20 million for the second half of the fiscal year 2023, which increased by $2.02 million, or 170.3% from $1.18 million for the first half of the fiscal year 2023.

Our cost of revenues were $4.39 million for the fiscal year 2023 ended December 31, 2023, which increased by $1.01 million, or 29.6% from $3.38 million for the same period of 2022. The increase of the cost of revenues is due to the growth of revenues in the second half year of the fiscal year 2023 and a termination of a sub-contractor due to delayed progress which created higher cost of new engagements for the replacement and caught up the delays in the first half year of the fiscal year 2023.

Gross profit

Our gross profit was $2.19 million for the second half of the fiscal year 2023, which increased by $1.94 million, or 766.6% from $0.25 million for the first half of the fiscal year 2023.

Our gross profit was $2.44 million for the fiscal year 2023 ended December 31, 2023, which increased by $1.65 million, or 210.6% from $0.79 million for the same period of 2022. The significant increase of gross profit margin was caused by the demand of charge to client for the unilaterally suspension.

General and administrative expenses

General and administrative expenses amounted to approximately $1.00 million for the second half of the fiscal year 2023, which decreased by $0.89 million, or 47.4% from $1.89 million for the first half of the fiscal year 2023.

General and administrative expenses amounted to approximately $2.89 million for the fiscal year 2023 ended December 31, 2023, which increased by $1.46 million or 102.6% from $1.43 million for the same period of 2022. This increase was mainly due to the increase of cost after listing, the related cost such as listing fee, legal and professional fees, and salary payment.

General and administrative expenses include rental expenses, staff salary and benefits, legal and professional fees, office expenses, travel expenses, entertainment, depreciation and listing fees.

Interest Expenses

Interest expenses amounted to $36,967 for the second half of the fiscal year 2023, which increased by $12,370, or 50.3% from $24,597 for the first half of the fiscal year 2023.

Interest expenses amounted to $61,564 for the fiscal year 2023 ended December 31, 2023, which increased by $26,187, or 74.0% from $35,377 for the same period of 2022. During the fiscal year of 2023, we engaged into an additional bank facility to allow the group to increase the utilization of debt equity ratio, while also allowed us to offset the interest rate risk by in-house interest rate hedged.

Other Income

Other income amounted to $141,923 for the second half of the fiscal year 2023, which increased by $100,046, or 238.9% from $41,877 for the first half of the fiscal year 2023.

Other income amounted to $183,800 for the fiscal year 2023 ended December 31, 2023, which increased by $103,852, or 129.9% from $79,948 for the same period of 2022.

Net loss

Net profit was $1.30 million for the second half of the fiscal year 2023, which increased by $2.92 million, or 179.8% from net loss of $1.62 million for the first half of the fiscal year 2023.

Net loss was $0.33 million for the fiscal year 2023 ended December 31, 2023, which increased by $0.27 million, or 45.0% as compared to $0.60 million for the same period of 2022.

Equity

Our Shareholders’ Equity increased by 28.4% and 449.0% to $5.98 million for the fiscal year 2023 ended December 31, 2023, from $4.66 million for six months ended June 30, 2023 and deficit of $1.71 million for the year ended December 31, 2022 respectively.

About WANG & LEE GROUP, Inc.

MARPAI INC. ANNOUNCES SALE OF $11.83 MILLION CONVERTIBLE NOTES
Financing Strengthens Marpai's Growth Trajectory

TAMPA, Fla., April 16, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an independent national Third-Party Administration company transforming the $22 billion TPA market supporting self-funded employer health plans with affordable, intelligent, healthcare, today announced the sale of new three-year, $11.83 million convertible notes to funds managed by JGB Management Inc.

The loan proceeds will be used to repay Marpai's existing debt with Libertas Funding, fuel Marpai's ongoing growth initiatives and bolster working capital.

Key Highlights of the Loan Agreement:

Total Loan Amount: $11.83 million
Term: Three years
Use of Proceeds: Debt repayment, growth initiatives and working capital
Convertible Note Provision: The notes are convertible into Marpai common stock at a price of $3.00 per share. This represents a premium to the current market price of Marpai's common stock. The convertible note also provides for price protection in the event Marpai issues shares below the applicable conversion price subject to the floor of $2.23 per share.
"The proceeds from the sale of the convertible notes provides us with the financial flexibility to accelerate our growth strategy and further solidify our position as a leader in the self-funded employer health plan market," said Damien Lamendola, CEO of Marpai.

Financing Strengthens Marpai's Growth Trajectory

Marpai has experienced significant growth in recent years, driven by its innovative technology platform and commitment to delivering cost-effective, high-quality healthcare solutions to self-funded employers. The Company is well positioned to capitalize on the increasing demand for self-funded health plans, and this new financing will provide Marpai with the resources needed to continue its upward trajectory.

The securities described herein have not been registered under the Securities Act of 1933, as amended, and may not be sold in the United States absent registration or an applicable exemption from the registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

ThinkEquity served as advisor to the company on the financing.

About Marpai, Inc.

Marpai, Inc. (Nasdaq: MRAI) is a leading, national TPA company bringing value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Marpai works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release.

Forward-Looking Statement Disclaimer

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward looking statements when it discusses the potential for ongoing growth initiatives, the expected use of proceeds and the belief that this strategic financing demonstrates JGB Management's confidence in its innovative approach to the TPA market and its future potential. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release.

Laser Photonics Provides Shareholder Letter and Announces Fourth Quarter and Year-End 2023 Results
Fourth quarter revenue grew by 673%

Fourth quarter operating and net losses improved by 36% and 86%, respectively

https://www.otcmarkets.com/stock/LASE/news/story?e&id=2825562

Monks, I dunno! Something bothers me about this Company. There are things I have read in PRs here that,,,, well kinda weird.. But I wanna do a full DD on this to make sure as it just might be just plain bad IR. Will post back next week. BTW did you happen to see that property in the D.M. that they wanna build on? OMG but is it real?
LOL

Let's see what happens after 4/12. Hope all is well Monks :)

LASER PHOTONICS CORP: Is Hiring
Recruiting Manager | Talent Acquisition | Full-Cycle Recruiter | Onboarding | Proactive Sourcing | Talent Networking | LinkedIn Recruiter | Employee Law & Regulations Hiring a new Industrial Sales Representative -Military Clearance in Orlando, Florida. Apply today or share this post with your network.
Laser Photonics Corporation
Industrial Sales Representative -Military Clearance
Job by Laser Photonics Corporation
Orlando, Florida, United States (On-site)
Jessica Morales
jessimorales01@hotmail.com

Listen, bro. They postponed their 4/1 earnings call. IMHO I don't think its gonna be too good however 2024 numbers should be spectacular! I already sold out for large gain and will buy in again after Earnings. If I am correct then we should see $1.50 again.

Laser Photonics Secures Order From L3Harris Technologies for LaserTower Marking & Engraving System
ORLANDO, Fla.--(BUSINESS WIRE)-- Laser Photonics Corporation (LPC) (NASDAQ: LASE), a leading global developer of industrial laser systems for laser cleaning and other material processing applications, announced that it received an order for its LaserTower COMPACT marking and engraving system from L3Harris Technologies, Inc.

“Laser Photonics is proud to supply laser marking equipment to L3Harris, one of the largest long-time defense contractors in the United States,” said Wayne Tupuola, CEO of Laser Photonics. “This deal underscores our commitment to excellence and innovation. We look forward to delivering cutting-edge solutions that will enhance their operations and contribute to forging a future that is safer and more technologically advanced.”

L3Harris will use LPC’s LaserTower COMPACT system at its semiconductor division in Palm Bay, Florida. The company focuses on command and control systems, precision munitions, avionics and electronic systems, and other specialized equipment for the government, defense and commercial sectors.

The LaserTower COMPACT is an industrial-grade laser marking, engraving and etching system that can operate as a stand-alone unit or get integrated into an I/O production line. Our LaserTower series offers effortless “plug and play” setup, user-friendly operation and enduring performance. It’s the ideal solution for precise, legible, permanent direct part marking, including UDI/UID barcodes, logos and other service marks for a wide range of materials. The system integrates LPC’s proprietary technology for easy barcode scanning.

For more information about the LaserTower line of laser marking and engraving systems, please visit https://www.laserphotonics.com or contact our sales department at fiberlaser@laserphotonics.com.

This 1-month run has been nothing short of outstanding!

Very interesting!

AUVI new 52-week low

Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) --
-- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually --

NEWTOWN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with Lovell Government Services (“Lovell”), an SBA-certified Service Disabled Veteran Owned Small Business (“SDVOSB”), to make the Company’s Portable Neuromodulation Stimulator (“PoNS®”) device available to federal healthcare systems. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used in conjunction with physical therapy.

“Through their Multiple Sclerosis Centers of Excellence, the VA is dedicated to maximizing the quality of life for veterans suffering from MS, and we are thrilled to partner with Lovell to expand the reach of our innovative PoNS device. In a study of real-world results, after 14 weeks of PoNS Therapy, 100% of MS patients experienced a clinically meaningful improvement in gait. More than 28,000 cases of MS are reported to the VA annually, making PoNS a potential game changer for veterans and their families,” said Dane Andreeff, President and Chief Executive Officer of Helius.

“As the largest integrated healthcare system in the U.S., the VA provides services to veterans with MS from the time of diagnosis through the rest of their lives. Veterans have given their best to our country and should have access to the most innovative and effective resources available. Lovell is proud to introduce this important product to the VA and other federal healthcare providers,” said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services.

“Recently, Helius highlighted the real-life story of Kevin Byrne, a retired U.S. veteran who’s been suffering from MS since 1999. Gait difficulties had taken away his most valued treasure, quality adventures with his 13-year-old daughter, but PoNS Therapy helped him improve his walking by increasing speed, endurance, and distance. After treatment with PoNS, he was able to take his daughter to New York City, where they enjoyed walking the streets and seeing Broadway shows, experiences he thought were lost forever. While clinical results have demonstrated the effectiveness of PoNS Therapy, it’s firsthand accounts like Captain Byrne’s that are the most gratifying,” concluded Andreeff.

MARPAI REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
Full Year Benefit of Maestro Acquisition and Q4 Corrective Actions Driving Financial Improvement

TAMPA, Fla., March 26, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans with affordable, intelligent healthcare, today announced financial results for the fourth quarter and fiscal year 2023. The Company expects to hold a webcast to discuss the results on March 27, 2024.

Q4 2023 Financial Highlights:

Net revenues were $8.7 million for the three months ended December 31, 2023, an improvement of $1.1 million, or 14% higher year over year, for the three months ended December 31, 2022.
Gross profit was $3.0 million for the three months ended December 31, 2023, an improvement of $0.2 million, or 6.5% higher year over year for the three months ended December 31, 2022.
Operating expenses were $8.2 million for the three months ended December 31, 2022, an improvement of $3.6 million, or 30.6% lower year over year for the three months ended December 31, 2022.
Operating loss was $5.2 million for the three months ended December 31, 2022, an improvement of $3.8 million, or 42.3% lower year over year for the three months ended December 31, 2022.
Net loss was $5.0 million for the three months ended December 31, 2022, an improvement of $3.5 million, or 41.1% lower year over year for the three months ended December 31, 2022.
Basic and diluted earnings per share were ($0.65) an improvement of $1.00 per share year over year for the three months ended December 31, 2022.
Full Year 2023 Highlights:

Net revenues were $37.2 million for the year ended December 31, 2023, an improvement of $12.8 million, or 52.6% higher year over year compared to the year ended December 31, 2022.
Gross profit was $12.9 million for the year ended December 31, 2023, an improvement of $5.7 million, or 79.2% higher year over year compared to the year ended December 31, 2022.
Operating expenses were $40.9 million, for the year ended December 31, 2023, an increase of $6.7 million, or 19.7% higher year over year compared to the year ended December 31, 2022. The $1.3 million variance for the operating expenses and operating loss from our previously announced preliminary results was due to the reclassification of $3.0 million goodwill impairment and $1.7 million gain on sale of our non-core FSA business.
Operating loss was $28.0 million for the year ended December 31, 2023, or an increase of $1.0 million, or 3.8% higher year over year compared to the year ended December 31, 2022.
Net loss was $28.8 million for the year ended December 31, 2023, an increase of $2.3 million, or 8.6% higher, compared to the year ended December 31, 2022.
Basic and diluted earnings per share were ($4.14) for the year ended December 31, 2023, an improvement of $1.09 per share compared to the year ended December 31, 2022.
"The Company delivered on several actions identified when the new executive team joined in early November 2023," said Damien Lamendola, Chief Executive Officer of Marpai. "We are starting to gain the benefits of the Maestro Health acquisition. We remain committed to our overall vision that Marpai Saves, through operational and financial improvements, reduces costs for our clients and improves the quality of care for our members."

Webcast and Conference Call Information

Marpai expects to host a conference call and webcast on Wednesday, March 27, 2024, at 8:30 a.m. ET to answer questions about the Company's operational and financial highlights for its fourth quarter and year ended December 31, 2023.

Investors interested in listening to the conference call may do so by dialing (800)-836-8184 for domestic callers or +1-646-357-8785 for international callers, or via webcast: https://app.webinar.net/8OgAYdJmbd9

About Marpai, Inc.

Marpai, Inc. (Nasdaq: MRAI) is a leading, national TPA company bringing value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Marpai works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release.

Forward-Looking Statement Disclaimer

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward looking statements when it discusses its financial results and that it remains committed to its overall vision that Marpai Saves, through operational and financial improvements, reduces cost for its clients and improving the quality of care for its members. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.



MARPAI, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(in thousands)




December 31, 2023


December 31, 2022

We will get compliant now!
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously reported, on September 19, 2023, the Company received written notice (the "Notice") from the Nasdaq Stock Market, LLC ("Nasdaq") indicating that the bid price for the Company's common stock (the "Common Stock"), for the last 31 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company was not in compliance with the $1.00 minimum bid price requirement for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").
On March 19, 2024, the Company received written notification from the Listing Qualifications Department of Nasdaq, granting the Company's request for a 180-day extension to regain compliance the Bid Price Rule. The Company now has until September 16, 2024, to meet the requirement. If at any time prior to September 16, 2024, the bid price of the Company's Common Stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Bid Price Rule.
If the Company does not regain compliance with the Bid Price Rule during the additional 180-day extension, Nasdaq will provide written notification to the Company that its Common Stock will be delisted. At that time, the Company may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance that, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful.
Nasdaq's extension notice has no immediate effect on the listing or trading of the Company's Common Stock, which will continue to trade on the Nasdaq Capital Market under the symbol “CURI”.
The Company intends to actively monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options to regain compliance with the Bid Price Rule under the Nasdaq Listing Rules.
Item 8.01 Other Events.

Laser Photonics Corporation Enters Distribution Agreement With Incredible Supply & Logistics for Its Military & Industrial Laser Solutions
ORLANDO, Fla.--(BUSINESS WIRE)-- Laser Photonics Corporation (NASDAQ: LASE) (LPC), a leading global developer of industrial laser systems for laser cleaning and other material processing applications announced today that it has entered into a distribution agreement with Incredible Supply & Logistics (ISL), an award-winning product distribution, mission kitting, and third-party logistics (3PL) company specializing in supporting federal government customers and defense contractors as well as serving the maritime & space communities.

“This partnership will increase our customer base and expand our distributor network while equipping an industry-leading supplier with the cutting-edge industrial laser solutions that Government and Defense clients have been demanding,” said Wayne Tupuola, CEO of Laser Photonics. “What underlies ISL’s success with these demanding, high-dollar niche markets is their uncanny ability to source an entire bill of materials from top to bottom more cost effectively than their competition. No items are too small, too big, too unusual, or too next-generation for them. We are excited to have a new partner working to provide world-class laser systems to a large, critical audience.”

ISL was featured on Industrial Distribution magazine’s 2018 Watch List, which shines a light on companies that are the “ones-to-watch” outside of the 50 biggest MRO distributors. Laser Photonics will benefit from the company’s exceptional federal subcontractor support relationships, experience and expertise which includes dozens of strong links to the U.S. Air Force, Army, Navy, Coast Guard, Defense Logistics Agency, Department of State, and Missile Defense Agency. LPC will also greatly benefit from ISL’s national distribution network, which includes a closely aligned supplier network, robust sourcing, manufacturing resources, and a team of subject matter experts and support personnel.

Laser Photonics joined with ISL in mid-February 2024. As part of this vendor agreement, the initial products that will be offered through ISL will include:

DefenseTech Handheld DT-50-CTHD Laser Cleaning System
DefenseTech Blaster Cabinet DT-50-BC Laser Cleaning System
MarkStar Handheld LPC-20-MSH Laser Engraving System
WeldTech LPC-1500-LWS Laser Welding System
Personal Protective Equipment (PPE)
Laser training for the products offered and more
About Laser Photonics Corporation

CuriosityStream Announces Fourth Quarter and Full Year 2023 Financial Results and Initiation of Dividend Program
SILVER SPRING, Md.--(BUSINESS WIRE)-- CuriosityStream Inc. (NASDAQ: CURI), a global factual entertainment company, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. In addition, the Company’s Board of Directors declared a quarterly cash dividend of $0.025 per share, with the first dividend payable on April 30, 2024, to stockholders of record on April 12, 2024. With the initiation of a cash dividend program, CuriosityStream intends to pay regular quarterly dividends.

“Our fourth quarter revenue results met our guidance range while adjusted free cash flow exceeded our guidance range, and we delivered sequential revenue growth in our Direct Business. We continued to decrease our cost base, as we achieved our fifth straight quarter of sequential adjusted free cash flow improvement,” said Clint Stinchcomb, President & CEO. “Looking forward, we will be guiding to positive adjusted free cash flow for the first quarter of 2024, and we believe the initiation of the dividend program, which will be paid from excess cash, underscores our positive outlook for cash flow in 2024.”

Fourth Quarter 2023 Financial Results

Revenue of $14.8 million, compared to $14.5 million in the fourth quarter of 2022;
Gross profit of $6.7 million, compared to $1.4 million in the fourth quarter of 2022;
Total advertising and marketing and general and administrative expenses of $11.4 million, a 32% year-over-year reduction;
Net loss of $4.7 million, compared to net loss of $14.5 million in the fourth quarter of 2022;
Net cash used in operating activities of $2.5 million, compared to net cash used in operating activities of $8.8 million in the fourth quarter of 2022;
Adjusted Free Cash Flow of $(2.4) million, compared to Adjusted Free Cash Flow of $(8.8) million in the fourth quarter of 2022;
Adjusted EBITDA of $(3.4) million, compared to Adjusted EBITDA of $(13.6) million in the fourth quarter of 2022; and
Cash and restricted cash balance of $38.2 million and no debt as of December 31, 2023.
Full Year 2023 Financial Results

Revenue of $56.9 million, compared to $78.0 million in 2022;
Gross profit of $21.3 million, compared to $26.5 million in 2022;
Total advertising and marketing and general and administrative expenses of $46.8 million, a 40% year-over-year reduction;
Net loss of $48.9 million, compared to net loss of $50.9 million in 2022;
Net loss included a $19.0 million charge related to the impairment of content assets;
Net cash used in operating activities of $16.2 million, compared to net cash used in operating activities of $39.5 million in 2022;
Adjusted Free Cash Flow of $(16.2) million, compared to Adjusted Free Cash Flow of $(39.7) million in 2022; and
Adjusted EBITDA of $(20.2) million, compared to Adjusted EBITDA of $(44.3) million in 2022.
Full Year 2023 Business Highlights

Premiered multiple groundbreaking original series and specials, including The Real Wild West, Deadly Science, The True Story of Pirates, Lift the Ice, Vikings: The Lost Kingdom, GIANTS, 2023:A Space Odyssey, History: The Interesting Bits, CSI On Trial, Nature's Hidden Miracles, Queens of Ancient Egypt, Rescued Chimpanzees of the Congo with Jane Goodall, Search for Earth’s Lost Moon, Scary Tales of New York, Connections with James Burke, AI Tipping Point, Amazing DinoWorld 2 and Top Science Stories of 2023.
Signed new licensing, Pay TV and AVOD agreements with several partners during the year;
Added hundreds of titles to underserved areas like hosted series, crime, aviation and automotive, and to core genres like history, science and tech;
Launched a series of annual promotional stunts showcasing our most engaging titles for subscribers across SPACE WEEK, DINO WEEK, ANCIENT EGYPT WEEK, JAWS & CLAWS WEEK, and EARTH MONTH.
Financial Outlook

CuriosityStream expects the following for the first quarter of 2024:

Revenue within the range of $11.5 - $12.5 million
Adjusted Free Cash Flow within the range of $0.25 - $1.00 million
Conference Call Information

CuriosityStream will host a Q&A conference call today to discuss the Company’s fourth quarter and full year 2023 results at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). A live audio webcast of the call will be available on the CuriosityStream Investor Relations website at https://investors.curiositystream.com. Participants may also dial-in toll free at (888) 510-2008 or International at (646) 960-0306 and reference conference ID# 3957505. An audio replay of the conference call will be available for two weeks following the call on the CuriosityStream Investor Relations website at https://investors.curiositystream.com.

Forward-Looking Statements

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, CuriosityStream’s expectations or predictions of future financial or business performance or conditions, plans to pay regular dividends, consumers’ valuation of factual content, and the Company’s continued success. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “predicts” or “intends” or similar expressions. Such forward-looking statements involve risks and uncertainties that may cause actual events, results or performance to differ materially from those indicated by such statements. Certain of these risks are identified and discussed under “Risk Factors” in CuriosityStream’s Annual Report on Form 10-K for the year ended December 31, 2023, that we expect to file with the Securities and Exchange Commission (the “SEC”) on or about March 22, 2024, and in CuriosityStream’s other SEC filings. These risk factors are important to consider in determining future results and should be reviewed in their entirety.

Forward-looking statements are based on the current belief of the management of CuriosityStream, based on currently available information, as to the outcome and timing of future events, and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. However, there can be no assurance that the events, results or trends identified in these forward-looking statements will occur or be achieved. Forward-looking statements speak only as of the date they are made, and CuriosityStream is not under any obligation, and expressly disclaims any obligation to update, alter or otherwise revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Readers should carefully review the statements set forth in the reports that CuriosityStream has filed or will file from time to time with the SEC.

In addition to factors previously disclosed in CuriosityStream’s reports filed with the SEC and those identified elsewhere in this communication, the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: (i) risks related to CuriosityStream’s ability to maintain and develop new and existing revenue-generating relationships and partnerships or to significantly increase CuriosityStream's subscriber base and retain customers; (ii) the effects of pending and future legislation; (iii) risks of the internet, online commerce and media industry; (iv) the highly competitive nature of the internet, online commerce and media industry and CuriosityStream’s ability to compete therein; (v) litigation, complaints, and/or adverse publicity; (vi) the ability to meet Nasdaq’s listing standards; and (vii) privacy and data protection laws, privacy or data

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease.

NEW YORK, March 19, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), is pleased to unveil positive pre-clinical research showcasing the potential of HT-ALZ, an innovative Alzheimer's disease therapeutic. Targeting the Substance P/Neurokinin 1 Receptor pathway, HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease.


This pioneering study, conducted by a distinguished team of researchers including Carla Yuede, Kate M. Reardon, Ryan T. Harrigan, and John R. Cirrito, among others, highlights HT-ALZ's profound impact on Alzheimer's pathology. By specifically antagonizing the NK1 receptor, HT-ALZ not only reduces soluble Aß levels in the brain's interstitial fluid but also significantly diminishes anxiety-like behavior and enhances cognitive function in preclinical models.

The research presents compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment. While the effects on plaque deposition and Aß levels were inconclusive, the treatment's cognitive benefits suggest that HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients.

HT-ALZ's pre-clinical significance lies in its ability to restore cognitive functions and improve quality of life for subjects suffering from Alzheimer's disease, offering a beacon of hope.

Hoth Therapeutics remains committed to further research and development of HT-ALZ, including detailed analyses of its effects on microglial activation and brain inflammation. The company is optimistic about HT-ALZ's path toward. The full manuscript of the study will be published later this year and we look forward to a presentation of the results by the scientists named above who will be sharing this data at an Alzheimer's Research Center group at Washington University in St Louis.

For more information on Hoth Therapeutics and our innovative approach to Alzheimer's disease treatment with HT-ALZ, please visit https://hoththerapeutics.com

About Hoth Therapeutics, Inc.

$HYSR is gonna explode!

The conference call will be at 5pmEST on Thursday. I won't be able to be on the call but will surely look at the transcript! Hope you're having a nice weekend!

$34.74 new 52-week high

$33.72 She is tearing up asks!!! :)

$28.06 = a new 52-week high!

NASDAQ PANEL GRANTS MARPAI'S REQUEST FOR EXTENSION TO COMPLY WITH CONTINUED LISTING REQUIREMENTS
TAMPA, Fla., March 13, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans with affordable, intelligent, healthcare, today announced that it received notice from the Nasdaq Hearings Panel ("Panel") of The Nasdaq Stock Market ("Nasdaq") that it has granted the Company an extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market (the "Panel Decision"), as discussed more fully below.

Subject to the Company meeting certain requirements by March 31, 2024, the Hearings Panel granted the Company an extension until May 28, 2024, to regain compliance with the Market Value of Listed Securities ("MVLS") requirement of $35,000,000 or satisfy any of the alternative requirements in Listing Rule 5550(b).

"The extension granted by the Nasdaq Hearings Panel will allow us to finish executing our plan to regain compliance with Nasdaq's minimum market value of listed securities requirement," said Damien Lamendola, CEO of Marpai. "Marpai has made significant progress on our plan to raise equity, improve operational efficiencies and drive growth through our recent customer renewals and wins."

As previously disclosed by the Company, on May 31, 2023, Nasdaq Listing Qualifications staff ("Staff") notified the Company that the market value of its listed securities ("MVLS") had been below the minimum $35,000,000 required for continued listing as set forth in Listing Rule 5550(b)(2). In accordance with Listing Rule 5810(c)(3)(C), the Company was provided 180 calendar days, or until November 27, 2023, to regain compliance. On November 28, 2023, the Staff notified the Company that it had determined to delist the Company as it did not comply with the MVLS requirement for listing on the Exchange. On November 29, 2023, the Company requested a hearing. A hearing on the matter was held on February 22, 2024, where the Company presented its compliance plan.

Notwithstanding the foregoing, there can be no assurance that the Company will be able to meet these deadlines or ultimately regain compliance with all applicable requirements for continued listing.

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
- Breakthrough Therapy Designation (“BTD”) provides an expedited review pathway, as well as increased access to U.S. Food and Drug Administration (“FDA”) guidance on trial design, with the potential to significantly reduce drug development timelines -

- First known BTD granted by the FDA for an adjunctive psychedelic based therapy for the treatment of Major Depressive Disorder (“MDD”) -

- Robust, sustained and statistically significant improvement in depression symptoms at four months with 75% of patients in remission from depression after two doses (16mg) -

- Impressive mean 22-point reduction in Montgomery-Asberg Depression Rating Scale (“MADRS”) score from baseline at four months -

- Data supports progression to a pivotal Phase 3 multinational study of CYB003 in MDD in mid-2024 -

- Achievement of milestones expedites and de-risks CYB003 development program -

- Company to host webcast to discuss CYB003 program updates today at 8:30 a.m. ET -

This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17, 2023, as amended December 22, 2023.

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the FDA has granted BTD to CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of MDD. If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240313731043/en/

https://mms.businesswire.com/media/20240313731043/en/2065181/4/CYBN_CYB003_Durability_Data_-_March_2024.jpg
Strong and durable effects 4 months after 2 doses (Graphic: Business Wire)

The Company also announced that its Phase 2 trial of CYB003 in MDD demonstrated robust and sustained improvement in depression symptoms at four months with 75% of participants receiving two 16mg doses achieving remission and no longer showing signs of depression.

These significant milestones reflect the Company’s commitment to advancing cutting-edge treatment options for MDD, marking a transformational moment in the pursuit of regulatory approval.

Breakthrough Therapy Designation Accelerates and De-risks the Path Forward6

BTD provides an expedited review pathway, as well as increased access to FDA guidance on trial design, with the potential to reduce drug development timelines. It is reserved for drug candidates that target serious conditions and demonstrate substantial improvement on a clinically significant endpoint over available therapies. The designation includes all “fast track” program features, as well as more intensive FDA guidance and discussion of the CYB003 development program, including planned clinical trials and plans for expediting the manufacturing development strategy.

The designation of CYB003 as a breakthrough therapy acknowledges the significant unmet medical need for more effective treatments of MDD and supports CYB003’s potential for significant improvements over existing therapies. BTD serves as validation of the Company’s progress to date and is expected to accelerate Cybin’s mission to advance its proprietary next-generation treatment towards new drug approval on an expedited basis.

This designation is supported by the positive topline results from the Company’s Phase 2 study of CYB003 in MDD, which demonstrated an improvement in depression symptoms superior to approved antidepressants and recently reported data with other psychedelics.1

“It is a testament to the hard work and dedication of the entire Cybin team that we have accomplished so much so quickly. The granting of Breakthrough Therapy Designation by the FDA underscores the potential of CYB003 to fill a gap in the treatment landscape for MDD and serves to expedite and de-risk our development program going forward,” stated Doug Drysdale, Chief Executive Officer of Cybin. “This designation provides for a streamlined review process and enhanced engagement with the FDA. With the robust durability data from our Phase 2 study in hand, we are ready to move forward expeditiously. We are grateful for the opportunity to accelerate the development and regulatory review process that this designation affords, as we prepare to advance CYB003 toward a Phase 3 pivotal trial around mid-year.”

“Currently available standard treatments for MDD can be limited in efficacy, remission and response rates, presenting challenges for patients and mental health practitioners alike. CYB003 may have potential to address these challenges, and with the FDA’s Breakthrough Therapy Designation, the regulatory path forward is accelerated,” said Dr. Maurizio Fava, M.D., Chair of the Department of Psychiatry and Psychiatrist-in-Chief at Massachusetts General Hospital.

Positive Four-Month Efficacy Data for CYB003

Robust and sustained improvements in symptoms of depression with two doses of 12 mg or 16 mg of CYB003: Mean reduction from baseline in the MADRS total score was approximately 22 points from baseline in both dosing cohorts. Approximately 75% of the patients were responders (>/= 50% improvement in MADRS scores) following two doses of 16mg. 60% of patients on 12 mg and 75% on 16 mg were in remission from depression following 2 doses (MADRS score
Safety and tolerability:

CYB003 was well tolerated with no drug-related serious adverse events.
All adverse events were mild or moderate in intensity.
No incidents of suicidal ideation or behavior.
No discontinuations due to adverse events.
"The sustained reduction in depression symptoms at the four-month mark after just two doses of CYB003 is a critical milestone, that demonstrates the durability of the response, following the rapid improvement in symptoms. It also paves the way for a change in the treatment paradigm for MDD. Unlike currently approved adjunctive treatments which require chronic, daily dosing, CYB003 allows for intermittent dosing without the challenges of withdrawing patients from their existing medications,” stated Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer of Cybin. “Notably, the durability data showed that at four months, approximately 75% of patients were responders, meaning that they achieved an improvement of 50% or greater in their MADRS scores. Across the two dosages, we also observed that at four months, 60% of patients receiving 12 mg and 75% receiving 16 mg achieved a MADRS score of less than or equal to 10, indicating that they were in remission and no longer showing signs of depression. Considering these positive findings, we are eager to progress the program and bring relief and treatment alternatives to the millions of people who can benefit,” concluded Mr. Inamdar.

“It is truly remarkable that at four months the participants experienced a sustained reduction and incremental improvement in depression symptoms,” continued Drysdale. “Impressively, the mean reduction from baseline in the MADRS total score was approximately 22 points at 4 months (compared to a mean reduction of 14 points vs placebo and 17 points from baseline at 3 weeks). This is highly encouraging, especially for patients who have not responded to existing treatment options. We look forward to initiating our Phase 3 trial, which we anticipate will be an international, multisite study to further evaluate the safety and efficacy of CYB003 capsules in a larger MDD patient population. As we advance this program, we are proud to lead the way and contribute to the growing body of scientific evidence supporting the therapeutic potential of psychedelic drugs to treat a multitude of mental health disorders,” concluded Drysdale.

The MADRS is a 10-item, clinician-administered scale designed to measure overall severity of depressive symptoms in subjects with MDD. It is widely used in clinical trials and accepted by regulatory authorities worldwide as a measure of symptoms of depression. The MADRS includes items ranging from sadness of mood, reduction in sleep and appetite, to difficulties in concentration, anhedonia, and negative and suicidal thoughts that are scored from 0 to 6, giving a total score ranging from 0 to 60. Typical score ranges for severity are: 0-6 normal; 7-19 mild; 20-34 moderate; and >34 severe depression. In the CYB003 study, mean baseline total scores on the MADRS were 31.4 to 33.7 in the active group and 30.8 in the placebo group.

Significant Unmet Medical Need in Depression

Depression is the leading cause of disability due to mental illness 2 and affects over 300 million people worldwide.3 Despite the use of currently available treatments such as selective serotonin reuptake inhibitors (“SSRIs”), up to two-thirds of patients with depression do not achieve remission with initial antidepressant treatment.4 Over 43 million Americans take antidepressants and over 70% of these individuals are treated with SSRIs.5 The BTD of CYB003 as an adjunctive therapy for MDD underscores the urgent need to address this treatment gap, as a significant proportion of people do not experience relief with existing therapies.

Conference Call and Webcast Details:

Date: Wednesday, March 13, 2024

Time: 8:30 a.m. ET.

Dial-in: 800-267-6316 (U.S. Toll-Free) or 203-518-9783 (International)

Conference ID: CYBN0313

Webcast: Register for the webcast here

The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

Notes:

Stone et al. (2022) Response to acute monotherapy for major depressive disorder in randomized, placebo-controlled trials submitted to the US Food and Drug Administration: individual participant data analysis. BMJ (Clinical research ed.), 378, e067606.
GBD 2019 Diseases and Injuries Collaborators (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396: 1204–22.
Friedrich M. J. (2017). Depression Is the Leading Cause of Disability Around the World. JAMA, 317(15), 1517. https://doi.org/10.1001/jama.2017.3826.
Rush et al. Am J Psychiatry 2006; 163:1905–1917.
Sood et al. (2023). Selective serotonin reuptake inhibitor use, age-related neuropathology and cognition in late-life. Psychiatry Research 328.
There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assume the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company’s development efforts to date.
About Cybin

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of MDD and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.

Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s planned clinical trials and plans for expediting manufacturing and development strategy for CYB003; the potential for CYB003 to provide significant improvement over existing therapies; the advancement of CYB003 toward a Phase 3 trial in mid-2024; the potential reduction in drug development timelines afforded by BTD; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of COVID-19 on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2023 year, and the Company’s annual information form for the year ended March 31, 2023, which are available under the Company's profile on www.sedarplus.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The FDA, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific

$BFYW Takes Steps to Implement Its Growth Initiative Further https://www.einnews.com/pr_news/694993430/bfyw-takes-steps-to-implement-its-growth-initiative-further

NEWS
Tenon Medical Reports Fourth Quarter and Full Year 2023 Financial Results
Fourth Quarter 2023 Revenue Increased 192% Year-Over-Year
Full Year 2023 Revenue Increased 324% Year-Over-Year
Surgical Procedures Increased 179% Year-Over-Year in the Fourth Quarter and 312% for the Full Year 2023
Achieved Three Consecutive Quarters of Positive Gross Profit Margin in 2023
Catamaran® SI Joint Fusion System Included in a Series of Immersive Physician Webinar Training Programs Attended by Sixty Healthcare Providers in Q4
LOS GATOS, CA / ACCESSWIRE / March 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Fourth Quarter & Full Year 2023 and Subsequent Highlights

Revenue of $808,000 in the fourth quarter of 2023, a 192% increase over the prior year quarter.
Revenue of $2.9 million in 2023, a 324% increase from the full year of 2022.
Gross profit increased to $1.2 million as compared to a gross loss of ($641,000) in the full year of 2022.
Gross profit margin of 69% in the fourth quarter of 2023, a notable increase as compared to 57% in Q3 2023.
312% increase in the number of surgical procedures in which the Catamaran System was used compared to the prior year.
Participated in a series of immersive physician webinar training programs featuring the Company's Catamaran® SI Joint Fusion System in Q4.
Subsequent to year end, Tenon issued approximately $3.85 million of Series A Preferred Stock raising approximately $2.6 million in gross proceeds and retiring $1.25 million in secured debt.
Steve Foster, President and Chief Executive Officer of Tenon Medical, commented, "Tenon's strong fourth quarter and full year of 2023 was underscored by solid momentum in revenue, gross profit and gross margin, with fourth quarter's solid performance driven by a 312% year-over-year increase in surgical procedures utilizing The Catamaran System. In tandem, fourth quarter revenue increased 192% to $0.8 million, and full year 2023 achieved a 324% revenue increase to $2.9 million from 2022. Our notable achievement of three consecutive quarters of positive gross profit resulted in full year 2023 gross profit of $1.2 million and is a key performance metric we utilize for internal goal setting. Gross margin followed as well, achieving 69% in the fourth quarter, a striking sequential increase from 57% in Q3 2023.

Our results throughout 2023, our first full year of commercialization, were driven by the successes of our sales and marketing team, and a cadence of targeted physician workshop activities including a fourth quarter webinar series attracting over sixty healthcare providers interested in the simple inferior-posterior implantation technique of our unique transfixing SI joint implant. For the full year, we hosted 133 physicians in Catamaran focused training sessions.

Additionally, throughout 2023, we successfully secured capital that has positioned our balance sheet to support our accelerated sales and marketing initiatives to advance the commercialization of the Catamaran System. We are appreciative of the confidence in our SI products as represented by our supportive and prominent investor syndicate. Importantly, our $1.25 million secured note financing led by Ascent Special Ventures in November 2023 has been fully repaid with the issuance in February 2024 of Series A Preferred Stock to the investors in such financing."

Mr. Foster continued, "Moving into 2024, we will leverage all we've learned in our first full year of commercialization by listening intently to our physician customers. Additionally, we will expand our educational activities to encompass the full suite of applications of our unique technology and we will continue to refine our instrument and implant offerings. We continue to make progress on our post-market multi-center study and expect a preliminary glimpse of this important data in the coming weeks.

Over the long-term, our goal is to further expand our product portfolio to address SI Revision with our innovative patent protected technology. Taken together, we are proud of our 2023 accomplishments including the revenue ramp and attractive gross profit from increased awareness and adoption of The Catamaran System. We've positioned Tenon's balance sheet and operating structure to drive continued revenue growth in 2024 as we continue to pursue a long-term value proposition for all stakeholders," concluded Foster.

Fourth Quarter & Full Year 2023 Financial Results

Revenue was $808,000 in the fourth quarter of 2023, an increase of 192%, compared to $277,000 in the comparable year ago period. Revenue was $2.9 million in the year ended December 31, 2023, an increase of 324%, compared to $691,000 in year ended December 31, 2022. The increase in revenue for the year ended December 31, 2023, as compared to 2022, was primarily due to an increase of 312% in the number of Catamaran System surgical procedures.

Gross profit in the fourth quarter of 2023, was $559,000, or 69% of revenues, compared to a gross loss of ($207,000), or (75)% of revenues, in the comparable year ago quarter. Gross profit in the year ended December 31, 2023, was $1.2 million compared to a gross loss of ($641,000) in the year ended December 31, 2022. Gross profit and gross margin percentage improved due to higher revenue associated with the increase in the number of surgical procedures and the anticipated benefit of lower standard costs.

Operating losses totaled $3.1 million for the fourth quarter of 2023, compared to a loss of $7.9 million in the fourth quarter of 2022. For the year ended December 31, 2023, operating losses totaled $15.7 million compared to $18.7 million in the prior year period. Decreases in operating expenses were primarily a result of decreases in sales and marketing expenses, primarily due to the terminated agreement with a distribution partner in the prior year and decreases in general and administrative expenses.

Net loss was $3.1 million for the fourth quarter of 2023, compared to a loss of $7.9 million in the same period of 2022. For the year ended December 31, 2023, net loss was $15.6 million, compared to $18.9 million in the prior year. The Company expects to incur additional losses in the future.

As of December 31, 2023, cash and cash equivalents totaled $2.4 million, as compared to $2.1 million as of December 31, 2022. As of December 31, 2023, the Company had $1.2 million of outstanding debt in the form of a secured note which has been fully repaid subsequent to year end.

Q4 2023 Earnings Conference Call

Management will host an investor conference call at 4:30 p.m. ET (1:30 p.m. PT) today, Tuesday, March 12, 2024, to discuss Tenon's fourth quarter and full year 2023 financial results, provide a corporate update, and conclude with Q&A with the Company's covering analysts. To participate, please use the following information:

Date: Tuesday, March 12, 2024
Time: 4:30 p.m. Eastern time
Dial-in: 1-877-407-0792
International Dial-in: 1-201-689-8263
Webcast: TNON Conference Call
Please dial in at least 10 minutes before the start of the call to ensure timely participation.

An audio playback of the call will be available through March 26, 2024, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13744319.

About Tenon Medical, Inc.

Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran™ Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Tenon is underway with a national launch of this system to address the greatly underserved market opportunity that exists in this space. For more information, please visit www.tenonmed.com.

The Tenon Medical logo and Tenon Medical, are registered trademarks of Tenon Medical, Inc. Catamaran is a trademark of Tenon Medical, Inc.

Safe Harbor

This press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our Annual Report on Form 10-K on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled "Risk Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.

Investor Contact:

Shannon Devine
MZ North America
203-741-8811
tenon@mzgroup.us

Tenon Medical, Inc.

Minim Announces Merger Agreement with e2Companies
Merger to create NASDAQ-listed, comprehensive proprietary products and services company focused on Automated Grid Stability
MANCHESTER, N.H., March 12, 2024 (GLOBE NEWSWIRE) -- Minim, Inc. (“Minim”) (NASDAQ: MINM) today announced that it has entered into a definitive merger agreement with privately held e2Companies, LLC (“e2Companies”), to combine the companies in an all-stock transaction. The combined company will focus on continuing to drive proprietary solutions for grid modernization. Upon closing, which is currently anticipated in the second quarter of 2024, the combined company is expected to operate under the name e2Companies, Inc., and trade on the Nasdaq Capital Market.

“This agreement comes at a pivotal time for e2Companies as we advance the commercialization of our technology platform,” said James Richmond, CEO and President of e2Companies. “The aging infrastructure of our country’s grid and the increased need for demand-side innovation is critical. Our merger with Minim should allow us to accelerate AI data-driven networking solutions for the people that need it most, our customers.”

David Lazar, Co-CEO of Minim, commented, “After running a very thorough merger process, we are extremely excited to announce this transaction. We believe that e2Companies could disrupt the energy sector by providing Grid 3.0 energy solutions.”

About the Proposed Transaction, Management and Organization

Under the terms of the Agreement and Plan of Merger, e2Companies will merge with and into a wholly owned subsidiary of Minim, and as the surviving entity, e2Companies will become a wholly owned subsidiary of Minim. At the effective time of the merger, each common unit of e2Companies issued and outstanding will be converted into common stock of Minim based on a fixed exchange ratio, with any resulting fractional shares to be rounded to the nearest whole share. Interest holders of e2Companies will own approximately 97% of the combined company and securityholders of Minim will own approximately 3% of the combined company, on a fully diluted basis.

Following the merger, Minim, Inc. will be renamed “e2Companies, Inc.” and the corporate headquarters will be located at 8901 Quality Rd, Bonita Springs FL 34135. The combined company’s Board of Directors after the Merger will consist of seven members, two of whom will be designated by Minim.

The combined company will be led by James Richmond, CEO of e2Companies and creator of the world’s first Virtual Utility®. James brings a wealth of leadership experience across a wide range of industries, including 30 years of developing new engineering capabilities and innovative solutions for his customers in the energy industry.

“We are thrilled that James has agreed to lead the combined company,” said David Lazar, Co-CEO of Minim Inc.

The transaction has been approved by the Board of Directors of Minim and the managers of e2Companies and is expected to close in the second quarter of 2024, subject to customary closing conditions, including the effectiveness of the registration statement on Form S-4 to be filed by Minim and the approval by Minim stockholders.

ABZ Law Office is serving as legal counsel to Minim. Haynes and Boone, LLP is serving as legal counsel to e2Companies.

About Minim

Minim, Inc. (NASDAQ: MINM) is the creator of intelligent networking products that dependably connect people to the information they need and the people they love. Headquartered in Manchester, NH, the company delivered smart software-driven communications products under the globally recognized Motorola brand and Minim® trademark. Minim end users benefit from a personalized and secure Wi-Fi experience, leading to happy and safe homes where things just work.

To learn more about Minim, visit https://www.minim.com

About e2Companies

e2Companies is the first vertically integrated Virtual Utility® for power generation, distribution, and energy economics in the marketplace. e2Companies’ patented technology, the R3Di® System, provides a synthetic utility BUS with inertia for continuous on-site power and seamless resiliency, independent of grid conditions. The R3Di® System is continuously monitored by the Grove365 to optimize resources, track ESG targets, and unlock new revenue opportunities for customers. This automated platform is self-sust

Yup, a very nice run closed at $2.02 and not many investors know yet that it is Friday after-hours. Monday should be very sweet!
Thank you and very same to you😁

Now take a look at this! The CEO bought 910,000 shares at $1.65 on yesterday's dip! https://www.otcmarkets.com/filing/html?id=17354918&guid=C3d-kpE91wv_B3h

I Hope you are doing fine!!!

That Stephen James Coffee is superb! It's some strong Java! Their stock looks much better since Monday

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms today announced the publication in Clinical Cancer Research, a journal of the American Association for Cancer Research, a paper titled “Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia.” The paper details preclinical studies by CERo analyzing its lead clinical candidate CER-1236 in targeting Acute Myelogenous Leukemia (AML) tumor cells from human patients, and the candidate’s killing effects on these tumor cells. The results in the paper found that the target for CER-1236 is found in the large majority (83%) of leukemic cells extracted from the bone marrow from patients, and that more importantly CER-1236 effectively eliminated leukemic cells in the company’s experiments. Finally, the target for CER-1236 was found by CERo to be highly expressed and detectable across common AML genetic classification subtypes, including patient samples with adverse risk mutations in TP53, ASXL1 and RUNX1.

“This new publication provides support for our plans to test CER-1236 in AML patients in our planned Phase I clinical trial, and moreover extends the scientific data we have produced showing the target for CER-1236 is present on tumor cells from diverse cancers, including ovarian, non-small cell lung cancer (NSCLC), and B cell malignancies,” said Daniel Corey M.D, Ph.D, CERo’s Founder and Chief Technology Officer.

“We’re very pleased with this publication in Clinical Cancer Research supporting our near term plans to advance CER-1236 into the clinic. As we have previously reported, CERo plans to file an Investigational New Drug (IND) application in the first half of 2024, and is targeting initial treatment of AML patients as well as B Cell lymphoma patients before the end of the year,” said Brian G Atwood, CERo’s Chairman and Chief Executive Officer.

Laser Photonics Receives Dual Order From Mine System Solutions for Laser Cleaning and Marking Systems
ORLANDO, Fla.--(BUSINESS WIRE)-- Laser Photonics Corporation (LPC) (NASDAQ: LASE), a leading global developer of industrial laser systems for cleaning and other material processing applications, announced today that it has received an order from Mine System Solutions (MSS) for its CleanTech 3000-CTHD laser cleaning system and its MarkStar Pro laser marking and engraving system.

"Laser Photonics was the preferred choice for MSS due to our technology's ability to be used for numerous applications in the mining industry," said Wayne Tupuola, CEO of Laser Photonics. "Our CleanTech and MarkStar technology provided the company with high-quality, precise solutions that are cost-effective, operator-safe and environmentally friendly."

MSS, based in Boonville, Ind., provides repairs and upgrades for mining equipment, from heavy equipment servicing to complete remanufacturing. The company strives to offer the mining industry safety and quality that matches or exceeds original equipment manufacturing at a fraction of the cost. MSS will use Laser Photonics' CleanTech and MarkStar systems in a range of its services, including repair and remanufacturing. The company will also utilize the laser technology to upgrade and improve existing processes for enhanced performance.

For more information about the CleanTech line of laser cleaning systems or the MarkStar family of marking and engraving equipment, please visit https://www.laserphotonics.com or contact our sales department at fiberlaser@laserphotonics.com.

52-week high has been SHATTERED!

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
the study, which is the largest reported trial to date of CAR T therapy for solid tumors, evaluated CAR T cells engineered to target the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Ra2), a product invented at City of Hope and exclusively licensed by Mustang Bio Inc. (Nasdaq: MBIO), a Fortress Biotech Inc. (Nasdaq: FBIO) Company.
https://www.businesswire.com/news/home/20240307463963/en/

LMFAO>

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
https://www.otcmarkets.com/stock/IMRN/news/story?e&id=2788683

Seasoned Investment Banker Dan McClory Acquires Majority Stake in Brera Holdings
Brera’s Executive Chairman triples his investment
DUBLIN, Ireland and MILAN, Italy, March 06, 2024 (GLOBE NEWSWIRE) -- Brera Holdings PLC (“Brera Holdings”, “Brera” or the “Company”) (Nasdaq: BREA) announces today that its Executive Chairman, Daniel J. McClory, an experienced figure in the investment banking world, has acquired a majority stake in Brera Holdings, the first publicly-traded multi-club ownership (“MCO”) company in global football (American soccer).

“I believe that this strategic move underscores the robust confidence Mr. McClory places in Brera's potential and heralds in a new era of international focus and expansion beyond the Company’s Italian roots,” stated Pierre Galoppi, Brera’s Chief Executive Officer.

Daniel J. McClory is an international investor, investment banker and venture philanthropist, who brings unparalleled expertise, vision, and commitment to Brera, as evidenced by this recent acquisition of 4,550,000 Class A Ordinary Shares, for a total holding of 6,850,000 Class A Ordinary Shares, cementing a 54.5% ownership position and securities entitling him to 83.7% of the total votes of the Company.

Mr. McClory has extensive experience founding and financing growth companies and executing equity capital markets and merger & acquisition transactions. Dan's principal and advisory deals have spanned North and South America, Europe, Africa and Asia. His teams have ranked in the Top Ten of league tables for placement agents and won “Deal of the Year” at the M&A Advisor Awards.

Dan has completed IPOs and transactions for clients listed on Nasdaq, the NYSE, the London Stock Exchange, Toronto Stock Exchange, the Stock Exchange of Hong Kong, Euronext Growth, and the Irish Stock Exchange. As Founder and CEO of Irvine, California-based Boustead & Company Limited, he has led the firm’s expansion into Singapore, the UK, Switzerland, Mauritius, Monaco and Latin America.

Mr. McClory serves on the Boards of the USA Track & Field Foundation, the Eastern Michigan University Champions Advisory Board, the American Foundation of Savoy Orders, and the Alder Foundation, where he listed the first-ever foreign-funded, venture philanthropy-backed IPO on Bovespa's Social Stock Exchange in Brazil. He is a dual U.S and Italian citizen.

Mr. Galoppi concluded, “This exciting development coincides with the welcoming of esteemed international business leaders to our Advisory Board, who not only support the Brera mission and understand the inimitable opportunities but are committed to enhancing our strategic capabilities to best position Brera for success. Together, we look forward to a future defined by growth, sustained innovation, and global reach, empowered by the trust and leadership of Mr. McClory and our all-star Advisory Board.”

I love it when total rubbish turns into Cabbage. :) Reminds me of a Superman episode when Professor Pepprwinkle built a machine that turned scrap metal into gold

Man, this baby is flying over $3.00 :)))

$BFYW Up tick on bid 003x0033 hoping for another good day